Cellebrite DI (CLBT) to Release Earnings on Wednesday

Cellebrite DI (NASDAQ:CLBT) will be issuing its quarterly earnings data before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.11 per share for the quarter. Cellebrite DI has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Thursday, August 15th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. The business had revenue of $95.70 million during the quarter, compared to the consensus estimate of $91.94 million. Cellebrite DI had a positive return on equity of 5,902.06% and a negative net margin of 28.51%. Cellebrite DI’s quarterly revenue was up 24.8% on a year-over-year basis. During the same period last year, the company earned $0.05 earnings per share. On average, analysts expect Cellebrite DI to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cellebrite DI Stock Performance

NASDAQ:CLBT opened at $18.55 on Tuesday. The company has a market cap of $3.82 billion, a PE ratio of -35.00, a PEG ratio of 2.50 and a beta of 1.50. Cellebrite DI has a 52-week low of $7.12 and a 52-week high of $18.75. The stock has a 50-day simple moving average of $17.47 and a 200 day simple moving average of $14.10.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CLBT. Needham & Company LLC increased their price objective on Cellebrite DI from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. raised their price target on Cellebrite DI from $14.00 to $15.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Bank of America raised their price target on Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Craig Hallum raised their price target on Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Finally, Lake Street Capital raised their price target on Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $18.57.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.